Targeting epidermal Langerhans cells by epidermal powder immunization

Chen, Dexiang; Payne, Lendon G.

doi:10.1038/sj.cr.7290115

Cited by 33 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been known that the epidermal layer harbors a variety of immunocompetent cells including epidermal Langerhans cells, which are major histocompatibity complex (MHC) class II-positive antigen-presenting cells; keratinocytes; and CD4 + and CD8 + T cells [22]. One hypothesis for the skin vaccination is that immunocompetent cells, most likely Langerhans cells, capture the antigens, which are subsequently delivered into local lymph nodes and prime immune responses [23]. By visualizing the expression of the β-galactosidase gene, we found that adenoviral vectors are able to deliver the genes across the skin and primarily appear in the epidermal layer.…”

Section: Discussionmentioning

confidence: 99%

A differential proteome in tumors suppressed by an adenovirus‐based skin patch vaccine encoding human carcinoembryonic antigen

Huang¹,

Shi²,

DeSilva³

et al. 2005

Proteomics

View full text Add to dashboard Cite

We created an anti-tumor vaccine by using adenovirus as a vector which contains a cytomegalovirus early promoter-directed human carcinoembryonic antigen gene (AdCMVhCEA). In an attempt to develop the skin patch vaccine, we epicutaneously vaccinated Balb/c mice with AdCMV-hCPA. After nine weeks post-immunization, vaccinated mice evoked a robust antibody titer to CEA and demonstrated the capability of suppressing in vivo growth of implanted murine mammay adenocarioma cell line (JC-hCEA) tumor cells derived from a female Balb/c mouse. Proteomic analysis of the tumor masses in the non-vaccinated naïve and vaccinated mice reveal that six proteins change their abundance in the tumor mass. The levels of adenylate kinase 1, β-enolase, creatine kinase M chain, hemoglobin beta chain and prohibitin were statistically increased whereas the level of a creatine kinase fragment, which is undocumented, was decreased in the tumor of vaccinated mice. These proteins may provide a vital link between early-stage tumor suppression and immune response of skin patch vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

A differential proteome in tumors suppressed by an adenovirus‐based skin patch vaccine encoding human carcinoembryonic antigen

Huang¹,

Shi²,

DeSilva³

et al. 2005

Proteomics

View full text Add to dashboard Cite

show abstract

“…By mechanically penetrating the cell membrane, the particles are delivered straight into the cytoplasm and/or the nucleus of the cells, thereby circumventing the suboptimal uptake of DNA from extracellular spaces. This allows for high immunogenicity at very low doses and superior induction of CTLs, but also antibodies (reviewed in [32]). These properties render gene gun immunization extremely interesting for immunization against pre-erythrocytic stages of malaria.…”

Section: Advanced Methods For Vaccine Applicationthe Biojector™ and Tmentioning

confidence: 98%

Genetic vaccination approaches against malaria based on the circumsporozoite protein

Scheiblhofer

Weiss

Thalhamer

2006

Wien Klin Wochenschr

View full text Add to dashboard Cite

Malaria is the world's major parasitic disease, for which effective control measures are urgently needed. Despite considerable efforts, no successful vaccine against malaria has been developed so far. The method of DNA-based immunization offers the possibility to induce both antibody- and cell-mediated immune responses to a variety of antigens. The flexibility of the DNA vaccine technology permits the combination of several antigens from different developmental stages of the parasite's complicated life cycle. This review covers the development of DNA-based immunization against malaria from initial experiments in small animals to recently conducted clinical studies. Focusing on one of the best characterized malaria vaccine candidate antigens, the circumsporozoite protein, an overview of strategies to enhance vaccine efficacy is provided. Advanced application methods such as the gene gun technology or the needle-less jet injection device are described. As DNA vaccination represents a relatively new methodology, safety concerns associated with planned clinical applications are discussed. In summary, this novel type of vaccine has to be considered as a promising tool for future malaria vaccination strategies.

show abstract

“…Antigen rapidly diffuses from the vaccination site, and is efficiently endocytosed by LCs. Initially, nearly all LCs in the vicinity of the target site can be shown to contain antigen [61]. Levels of antigen and antigen-containing LCs are high for 2 days following vaccination, and remain present at the site for ≤ 5 days.…”

Section: Delivery Of Protein Vaccines By Epidermal Powder Immunisationmentioning

confidence: 99%

Epidermal delivery of protein and DNA vaccines

Dean¹

2005

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Targeting vaccines to the skin epidermis results in the activation of an immune inductive site that is rich in antigen-presenting cells. The superficial location of the skin makes it accessible to vaccine delivery. However, it is difficult to access the epidermis using needle and syringe delivery, and vaccine antigens are too large to be effectively delivered using standard topical formulations. Needle-free vaccine delivery systems have been developed for efficient delivery of particulate vaccines into the epidermal tissue. Particle-mediated epidermal delivery of DNA vaccines is based on the delivery of DNA-coated gold particles directly into the cytoplasm and nuclei of living cells of the epidermis, facilitating DNA delivery and gene expression. Alternatively, protein vaccines can be formulated into a dense powder, which can be propelled into the skin epidermis by epidermal powder immunisation using similar delivery devices and principles, but in this instance the protein is delivered to the extracellular space. Preclinical and clinical data will be reviewed, demonstrating applications of epidermal vaccine delivery to a wide range of experimental infectious disease vaccines.

show abstract

Targeting epidermal Langerhans cells by epidermal powder immunization

Cited by 33 publications

References 46 publications

A differential proteome in tumors suppressed by an adenovirus‐based skin patch vaccine encoding human carcinoembryonic antigen

A differential proteome in tumors suppressed by an adenovirus‐based skin patch vaccine encoding human carcinoembryonic antigen

Genetic vaccination approaches against malaria based on the circumsporozoite protein

Epidermal delivery of protein and DNA vaccines

Contact Info

Product

Resources

About